MarketCap
Facebook
X
Telegram
Coherus BioSciences ROE Ratio | CHRS
Annual ROE Ratio Coherus BioSciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 275.39 | -21.6 | 122.99 | 212.31 | -293.78 | 47.07 | 85.38 | 542.46 | -779.99 | -657.94 | 3222.11 | -130.52 | 55.25 | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3222.11 | -779.99 | 206.09 |
Quarterly ROE Ratio Coherus BioSciences
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125.36 | 190.1 | 251.07 | 306.91 | -67.28 | -98.11 | -68.44 | -56.13 | -32.96 | 92.74 | 181.95 | 373.89 | -415.45 | -453.99 | -483.46 | -591.8 | -948.88 | -184.07 | -174.13 | -123.65 | -91.85 | 43.61 | 80.89 | 115.66 | 117.05 | 85.38 | 210.3 | -308.9 | -400.37 | 2087.81 | 1764.92 | 2054.05 | 1949.24 | -754.91 | -964.07 | -369.79 | -536.77 | -620.34 | 593.58 | 1333.91 | 2622.25 | 3596.91 | 2709.23 | 1548.2 | 563.36 | -130.44 | -71.79 | -37.89 | -37.68 | 15.03 | 22.12 | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3596.91 | -964.07 | 294.36 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Molecular Templates
MTEM
|
-192.88 | - | -23.43 % | $ 495 K |  USA |
 |
Vanda Pharmaceuticals
VNDA
|
-67.39 | $ 3.82 | 6.27 % | $ 225 M | USA |
 |
Verrica Pharmaceuticals
VRCA
|
-72.34 | $ 3.22 | 4.21 % | $ 34.3 M | USA |
 |
Viridian Therapeutics
VRDN
|
-47.44 | $ 28.47 | -0.28 % | $ 2.9 B | USA |
 |
BioXcel Therapeutics
BTAI
|
73.22 | $ 0.07 | 9.81 % | $ 855 K | USA |
 |
VistaGen Therapeutics
VTGN
|
-196.19 | $ 0.17 | 3.45 % | $ 6.47 M | USA |
 |
Voyager Therapeutics
VYGR
|
-61.06 | $ 1.86 | 8.14 % | $ 109 M | USA |
 |
CohBar
CWBR
|
-79.41 | - | -15.44 % | $ 2.2 M | USA |
 |
NeuBase Therapeutics
NBSE
|
-23.97 | - | -1.56 % | $ 12.3 M | USA |
 |
Gossamer Bio
GOSS
|
138.78 | $ 9.77 | 3.72 % | $ 2.23 B | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-55.55 | - | - | $ 2.18 B | USA |
 |
GeoVax Labs
GOVX
|
-561.15 | $ 0.16 | -5.0 % | $ 153 K | USA |
 |
Arena Pharmaceuticals
ARNA
|
-91.56 | - | -6.81 % | $ 3.04 B | USA |
 |
Scopus BioPharma
SCPS
|
176.86 | - | -48.37 % | $ 3.71 M | USA |
 |
Annovis Bio
ANVS
|
-171.23 | $ 0.82 | 23.72 % | $ 16.9 M | USA |
 |
scPharmaceuticals
SCPH
|
-639.25 | - | - | $ 218 M | USA |
 |
Xeris Pharmaceuticals
XERS
|
4.05 | $ 15.08 | 15.29 % | $ 2.42 B | USA |
 |
X4 Pharmaceuticals
XFOR
|
-42.51 | $ 3.15 | 2.61 % | $ 133 M | USA |
 |
Entasis Therapeutics Holdings
ETTX
|
-151.03 | - | - | $ 105 M | USA |
 |
Athersys
ATHX
|
304.11 | - | 3.77 % | $ 22.4 M | USA |
 |
Zai Lab Limited
ZLAB
|
-24.53 | $ 25.49 | 12.77 % | $ 27.9 B |  China |
 |
Zentalis Pharmaceuticals
ZNTL
|
-63.39 | $ 1.71 | 2.05 % | $ 123 M | USA |
 |
Zoetis
ZTS
|
80.25 | $ 79.51 | -3.21 % | $ 35.3 B | USA |
 |
Global Blood Therapeutics
GBT
|
-154.32 | - | - | $ 4.62 B | USA |
 |
Inozyme Pharma
INZY
|
-176.43 | - | - | $ 207 M | USA |
 |
Idera Pharmaceuticals
IDRA
|
-197.53 | - | -23.04 % | $ 26.6 M | USA |
 |
NanoString Technologies
NSTG
|
-348.24 | - | -37.43 % | $ 5.1 M | USA |
 |
Humanigen
HGEN
|
151.25 | - | -81.12 % | $ 4.28 M | USA |
 |
Sorrento Therapeutics
SRNE
|
3078.97 | - | -29.58 % | $ 126 M | USA |
 |
Surface Oncology
SURF
|
-68.08 | - | - | $ 59.7 M | USA |
 |
GlaxoSmithKline plc
GSK
|
39.41 | $ 50.28 | -0.27 % | $ 204 B |  Britain |
 |
Sierra Oncology
SRRA
|
-98.61 | - | -0.05 % | $ 1.34 B |  Canada |
 |
Cocrystal Pharma
COCP
|
-139.49 | $ 1.03 | 2.95 % | $ 11.6 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
-57.36 | $ 4.27 | 1.18 % | $ 348 M | USA |
 |
Vaccinex
VCNX
|
748.95 | - | -61.37 % | $ 654 K | USA |
 |
ImmuCell Corporation
ICCC
|
-3.84 | $ 9.9 | -0.5 % | $ 89.4 M | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
66.3 | - | -19.68 % | $ 18.4 M | Canada |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
Jounce Therapeutics
JNCE
|
-27.81 | - | - | $ 98.4 M | USA |
 |
Immutep Limited
IMMP
|
-42.77 | $ 3.25 | 20.82 % | $ 4.73 B |  Australia |
 |
Verona Pharma plc
VRNA
|
-84.78 | - | - | $ 69.7 B | Britain |
 |
Keros Therapeutics
KROS
|
28.7 | $ 9.32 | -1.43 % | $ 347 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
-169.83 | $ 7.19 | 2.71 % | $ 110 M | Australia |
 |
Corner Growth Acquisition Corp.
COOL
|
108.33 | - | -0.89 % | $ 114 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
12.23 | $ 306.2 | 2.41 % | $ 5.92 B | USA |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-256.9 | - | -11.43 % | $ 502 K | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-61.06 | $ 7.95 | 2.57 % | $ 535 B | Britain |
 |
Mersana Therapeutics
MRSN
|
727.65 | - | - | $ 3.56 B | USA |
 |
CymaBay Therapeutics
CBAY
|
-36.05 | - | - | $ 3.45 B | USA |